02. License for Biomaterials Yielded $1.75 Million for Cornell

Four patents for Cornell biomaterials technology licensed to MediVas, a privately held company in San Diego, California, resulted in $1.75 million in licensing payments to Cornell when MediVas sold the exclusive worldwide license to Guidant Corporation. MediVas developed new techniques for coating stents using technology from the laboratory of C.C. Chu, Textiles and Apparel. Chu and his research team developed an amino acid-based, highly elastic biomaterial that can coat stents to deliver nitric oxide (NO) derivatives to prevent the restenosis of an artery. Restenosis occurs in 30-45 percent of patients after balloon angioplasty procedures and placement of stents to open clogged arteries. Another class of the patented, licensed biomaterial is biodegradable hydrogels, which can improve the delivery of bioactive compounds in the body. They have potential for wound-care products and as substrates for tissue engineering to replace aged or diseased tissues or organs. Because of the high water retention ability of hydrogels, they may be useful for environment-friendly diapers and for agricultural devices.

› Back to Top  /  › Next Article  /  › Back to Listing

If you can see this message in a graphical web browser, then you are most likely using a non-modern browser. People who are using a graphical browser have the following options:

Upgrade to a modern generation web browser such as Mozilla, Opera, or for Mac users there is also Safari.

For people using early generation web browsers, such as Netscape 4, you can access the content of this page as is but there may be presentational errors.

Cornell University  
222 Day Hall
Ithaca, New York
14853-2801

P: 607.255.7200
F: 607.255.9030
E: VP Research
C: Credits

Cornell